Across TCGA pan-cancer cohorts, CT45A10 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CT45A10 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CT45A10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CT45A10 expression acts as an unfavorable survival marker.
HNSC are the cancer types where CT45A10 Mutation most reproducibly stratifies survival.